Bortezomib - National Cancer Institute - bortezomib breast cancer


bortezomib breast cancer - Bortezomib (Velcade) | Cancer in general | Cancer Research UK

Use in Cancer. Bortezomib is approved to treat: Mantle cell lymphoma in patients who have already received at least one other type of treatment. Multiple myeloma. Bortezomib is also being studied in the treatment of other types of cancer. More About Bortezomib. Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with at least one other medication. Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other medication.

Background: Bortezomib (VELCADE®) is a potent inhibitor of the 26S proteasome with broad antitumor activity. We performed a phase II study of bortezomib to evaluate its clinical effects in patients with metastatic breast cancer.Cited by: 142. Oct 15, 2010 · The incidence of bone metastasis in advanced breast cancer exceeds 70%. Bortezomib (Bzb), a proteasome inhibitor used for the treatment of multiple myeloma, also promotes bone formation. We tested the hypothesis that proteasome inhibitors can ameliorate breast cancer osteolytic disease.Cited by: 63.